Arjune's primary aim is to revitalise academic epileptology in Oxford. He is interested in cognitive, psychological and psychosocial difficulties in patients with epilepsy. He continues to delineate pathways that may cause neurodegeneration in epilepsy, aiming to develop treatments that may ameliorate both seizures and the co-morbidities that so commonly associate with epilepsy.
- Consultant Neurologist
- BRC Senior Research Fellow
Arjune trained at the University of Oxford, studying at Corpus Christi College. In his first summer in Oxford he completed a placement with Professor Simon Shorvon at The Institute of Neurology which essentially initiated all that has followed. Having completed an intercalated degree in Physiological Science, including a dissertation with Professor Colin Blakemore, he went to clinical school in Oxford before beginning medical training initially in Oxford and then in London.
In London, Arjune was trained predominantly at The Royal London Hospital and the National Hospital and undertook his PhD with the Department of Clinical and Experimental Epilepsy at Queen Square, sponsored by the MRC and the Guarantors of Brain, studying the molecular basis of neuronal loss in refractory epilepsy. Having completed Specialist Training and a Locum Consultant Posting at The National Hospital, he then went to Sydney during 2012, predominantly to learn to read Video-EEG during an Epilepsy Fellowship with Professor Ernie Somerville.
Arjune is now appointed as Consultant Neurologist at The John Radcliffe Hospital, NIHR BRC Senior Research Fellow in Epileptology and is Head of the Oxford Epilepsy Research Group
A neurological letter from Zimbabwe.
Sen A. et al, (2018), Pract Neurol
A clinical-grade gene therapy vector for pharmacoresistant epilepsy successfully overexpresses NPY in a human neuronal cell line.
Patrício MI. et al, (2018), Seizure, 55, 25 - 29
Hippocampal MRS and subfield volumetry at 7T detects dysfunction not specific to seizure focus.
Voets NL. et al, (2017), Sci Rep, 7
A point mutation in the ion conduction pore of AMPA receptor GRIA3 causes dramatically perturbed sleep patterns as well as intellectual disability.
Davies B. et al, (2017), Hum Mol Genet, 26, 3869 - 3882
Neuropsychiatric symptoms associated with Peramapnel usage in people with pharmacoresistant epilepsy: a case series of 10 patients
koychev I. et al, (2017)
Current Major Grants Awarded
'The immunological basis of pharmacoresistance in epilepsy' PIs: Arjune Sen, Sarosh Irani, Julian Knight. Funder: UCB Pharma £1.3M